Lonza to supply ingredients for 400 million doses of Moderna’s COVID vaccine annually

ZURICH (Reuters) – Swiss contract manufacturer Lonza’s facilities in Switzerland and the United States will be able to produce ingredients for 400 million doses of Moderna’s COVID-19 vaccine annually, the Swiss company said on Monday.

Lonza, which in September began “large-scale production” in the United States and expects Swiss production to start this year, made the announcement after Moderna said its vaccine candidate showed 94.5% efficacy, according to an interim data release.

(Reporting by John Miller; Editing by Michael Shields)